A vaccine is the only hope that is visible for defeating Covid-19. And many big companies are running in the race of the vaccine. Today, great news came regarding this. Pfizer and BioNTech are also working on a solution for covid-19. And Pfizer came forward today. They shared the great news that their solution is 90 percent effective in preventing Covid-19 infections in ongoing Phase 3 trials.
As the cases of Covid-19 are rising again. And many countries are facing 2nd wave of Covid-19. This news is a relief for all. According to preliminary findings, protection in patients was achieved seven days after the second of two doses. And 28 days after the first.
Official Statement by Pfizer
“The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19. We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We are reaching this critical milestone in our vaccine development program at a time when the world needs it most ” Pfizer Chairman and CEO Albert Bourla said in a statement.
After the first wave, the second wave is going to be worse. And hospitals are again going to fill and overload with patients. And death tolls will be on peaks again.
For the vaccine, there is a need for a huge supply. Companies are expecting to produce and supply almosyt 50 million vaccines in 2020. And 1.3 billion doses of the vaccines will be there in 2021.
US biotech firm Moderna, a few state-run Chinese labs, and a European task drove by the University of Oxford and AstraZeneca are believed to be surrounding possibly feasible immunizations.
Two Russian Covid-19 antibodies are already there for us even before clinical preliminaries. However, they are not much known outside of Russia.
The Phase 3 clinical preliminary – the last stage – of the new antibody, BNT162b2, started in late July. And has selected 43,538 members to date. 90% of these got a second portion of the immunization competitor as of November 8.
Pfizer said it is gathering two months of wellbeing information following the last portion – a prerequisite of the US Food and Drug Administration – to meet all requirements for Emergency Use Authorization, which it expects by the third week in November.
“We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks,” Bourla said.